Investigating tirzepatide's role in weight loss and metabolic health
- Eli Lilly filed lawsuits against four telehealth companies on Wednesday in California.
- These firms offer compounded versions of Lilly's weight loss and diabetes drugs following past shortages.
- Lilly alleges the companies deceive customers with untested formulations and control doctor prescribing decisions.
- Mochi CEO Myra Ahmad stated, "doctors get full autonomy" on patient formulations in March.
- Lilly seeks court orders stopping the firms from marketing or selling compounded tirzepatide.
22 Articles
22 Articles
Investigating tirzepatide's role in weight loss and metabolic health
Researchers at the Pennington Biomedical Research Center conducted a first-of-its-kind study to provide insights into the mechanisms of action of tirzepatide—a drug known as Zepbound—on weight loss with respect to energy expenditure, fat oxidation and calorie intake.
Eli Lilly sues companies selling alternative versions of its weight loss drug
The drug company Eli Lilly is suing four telehealth companies for allegedly selling copies made by compounding pharmacies of its drug Zepbound.(Image credit: Bloomberg/Bloomberg via Getty Images)
Eli Lilly is stepping up its fight against copycat weight-loss drugs
In its continuing war against copycat drugs, Eli Lilly (LLY) said on Wednesday that it filed suits against four telehealth companies that offer cheaper versions of its blockbuster GLP-1 weight loss drugs Mounjaro and Zepbound.Read more...
Coverage Details
Bias Distribution
- 67% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage